

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
<p>The public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing the burden, to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number.</p> <p>PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.</p>					
1. REPORT DATE (DD-MM-YYYY) 12-02-2008		2. REPORT TYPE MAJOR REPORT		3. DATES COVERED (From - To)	
4. TITLE AND SUBTITLE INCONTINCNTIA PIGMENTI				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) MAJ HSIEH DAVID T				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) CHILDRENS NATIONAL MEDICAL CENTER				8. PERFORMING ORGANIZATION REPORT NUMBER C108-0007	
9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES) THE DEPARTMENT OF THE AIR FORCE AFIT/ENEL, BLDG 16 2275 D STREET WPAFB OH 45433				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION/AVAILABILITY STATEMENT Unlimited distribution In Accordance With AFI 35-205/AFIT Sup 1 <div style="float: right; font-size: 2em; font-weight: bold; margin-top: 20px;">20080319422</div>					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT					
15. SUBJECT TERMS					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES 14	19a. NAME OF RESPONSIBLE PERSON
a. REPORT	b. ABSTRACT	c. THIS PAGE			19b. TELEPHONE NUMBER (Include area code)

SECURITY AND POLICY REVIEW WORKSHEET- Request for Public Release Clearance <i>(In Accordance With AFI 35-101, Chapter 15)</i> <i>(Do not use this worksheet to request clearance of software or web pages.)</i>			
SUBMITTING ORGANIZATION (Office Symbol) AFIT		080214	
A. DOCUMENT TYPE <i>(Documents must be complete including all figures, charts, photographs and text.)</i>			
<input type="checkbox"/> ABSTRACT <input type="checkbox"/> BROCHURES <input type="checkbox"/> CD-ROM <input type="checkbox"/> DISPLAY/EXHIBIT <input type="checkbox"/> FACT SHEET	<input type="checkbox"/> JOURNAL ARTICLE <input type="checkbox"/> NEWS RELEASE <input type="checkbox"/> PHOTO WITH CAPTIONS <input type="checkbox"/> POSTER SESSION <input type="checkbox"/> PRESENTATION WITH	<input type="checkbox"/> THESIS <input type="checkbox"/> SPEECH <input type="checkbox"/> SUCCESS STORY <input type="checkbox"/> TECHNICAL PAPER <input type="checkbox"/> TECHNICAL REPORT	<input type="checkbox"/> DISSERTATION <input checked="" type="checkbox"/> OTHER <u>Medlink Neurology</u>
B. TITLE OF DOCUMENT Incontinctia Pigmenti			NO. PAGES 14
C. AUTHOR(S) NAME AND DUTY TITLE Hsieh, David, Maj, USAF, MC, FS (Neurology Fellow), and Moorjani, Bhagwan (Neurology Attending)			OFFICE SYMBOL AFIT
D. FORUM <i>(Public release clearance is not required for material presented in a closed meeting and which will not be made available to the general public on the Internet or in any print or electronic media)</i>			
DOCUMENT WILL BE <input type="checkbox"/> PRESENTED ORALLY	NAME OF CONFERENCE	LOCATION	DATE
DOCUMENT WILL BE <input checked="" type="checkbox"/> DISTRIBUTED IN PRINT	NAME OF PUBLICATION Medlink Neurology, www.medlink.com		SUBMITTAL DEADLINE
HAVE RELATED DOCUMENTS BEEN PREVIOUSLY CLEARED FOR PUBLIC RELEASE <input checked="" type="checkbox"/> NO <input type="checkbox"/> YES AFIT CASE NUMBER _____			
NOTE: If document will be released to a medium outside the Department of Defense, the following disclaimer must be added: <i>The views expressed in this article are those of the author and do not reflect the official policy or position of the United States Air Force, Department of Defense, or the U.S. Government.</i>			
FOR AFIT/PA USE ONLY		<div style="background-color: #cccccc; padding: 5px; border: 1px solid black;"> SUBMIT TO: Air Force Institute of Technology Public Affairs (AFIT/PA) Building 642, Room 2010 2960 P Street Wright-Patterson AFB OH 45433-7765 </div> <div style="margin-top: 20px;"> FOR MORE INFORMATION Phone: (937) 255-9354 DSN: 785-9354 FAX: (937) 255-2135 DSN: 785-2135 E-MAIL: afit.pa@afit.edu WEB: http://www.afit.mil/newsrm01.htm </div>	

12 FEB REC'D

E. NATIONAL SECURITY AND TECHNOLOGY ISSUES

CHECK YES OR NO (Provide a brief explanation for all positive responses in the SYNOPSIS SECTION below.)

- ☐ YES ☒ NO DOES THE MATERIAL HAVE THE POTENTIAL TO BECOME AN ITEM OF NATIONAL OR INTERNATIONAL INTEREST.
- ☐ YES ☒ NO DOES THE MATERIAL AFFECT NATIONAL SECURITY POLICY OR FOREIGN RELATIONS.
- ☐ YES ☒ NO DOES THE MATERIAL CONCERN SUBJECTS OF POTENTIAL CONTROVERSY AMONG DOD COMPONENTS OR WITH OTHER FEDERAL AGENCIES.
- ☐ YES ☒ NO DOES THE MATERIAL CONTAIN TECHNICAL DATA DEVELOPED UNDER CONTRACT OR INDEPENDENTLY DEVELOPED AND CONTROLLED BY THE INTERNATIONAL TRAFFIC IN ARMS REGULATIONS (ITAR) THAT MAY BE MILITARILY CRITICAL AND SUBJECT TO LIMITED DISTRIBUTION, BUT ON WHICH A DISTRIBUTION DETERMINATION HAS NOT BEEN MADE.
- ☐ YES ☒ NO DOES THE MATERIAL CONTAIN INFORMATION ON NEW WEAPONS OR WEAPON SYSTEMS, SIGNIFICANT MODIFICATIONS OR IMPROVEMENTS TO EXISTING WEAPONS OR WEAPON SYSTEMS, EQUIPMENT OR TECHNIQUES.
- ☐ YES ☒ NO DOES THE MATERIAL CONTAIN INFORMATION ON NATIONAL COMMAND AUTHORITIES; COMMAND, CONTROL, COMMUNICATIONS, COMPUTERS AND INTELLIGENCE; INFORMATION WARFARE; OR COMPUTER SECURITY.
- ☐ YES ☒ NO DOES THE MATERIAL CONTAIN INFORMATION ON MILITARY ACTIVITIES OR APPLICATIONS IN SPACE, NUCLEAR WEAPONS, INCLUDING WEAPON-EFFECTS RESEARCH; CHEMICAL AND BIOLOGICAL WARFARE ISSUES; BIOLOGICAL AND TOXIN RESEARCH, HIGH-ENERGY LASERS AND PARTICLE BEAM TECHNOLOGY; ARMS CONTROL TREATY.

F. SYNOPSIS (Provide a brief description of the system, process, or technology, including its state of development and whether the application is military, commercial, or dual-use). EXAMPLE: This is new concept of applying current development for high-powered lasers, specifically for military applications.

G. REFERENCES (Check all that apply)

- ☒ ALL REFERENCES ARE UNCLASSIFIED, UNLIMITED, AND ARE AVAILABLE TO THE PUBLIC
- ☐ REFERENCE # ARE SUBJECT TO DISTRIBUTION LIMITATION. NO LIMITED INFORMATION FROM THESE REFERENCES IS INCLUDED IN THE DOCUMENT
- ☐ NO REFERENCES ARE INCLUDED IN THIS DOCUMENT

H. RELEASE AUTHORITY AND MANAGEMENT RESPONSIBILITY FOR JOINT EFFORTS

IS THIS INFORMATION CO-AUTHORED WITH SOMEONE FROM AN ORGANIZATION OUTSIDE OF AFIT.

☒ YES ☐ NO

DOES YOUR ORGANIZATION HAVE THE AUTHORITY TO RELEASE THE INFORMATION

☒ YES ☐ NO

IF WORK IS SPONSORED BY ANOTHER ORGANIZATION, DO YOU HAVE THE AUTHORITY TO RELEASE ALL THE INFORMATION

☐ YES ☐ NO

IF NOT, WHAT ORGANIZATION SHOULD COORDINATE ON THE REQUEST

ORGANIZATION

PHONE

NOTE: If the organization is a DOD organization, AFIT/PA will coordinate release approval with that organization's PA office

I. AUTHOR/TECHNICAL REVIEW CERTIFICATION	
AUTHOR	
I certify the information contained in the attached document is technically accurate and does not disclose classified, sensitive, or militarily critical technology and does not violate proprietary rights or copyright restrictions. All security and technology issues listed above have been considered and any applicable security classification guides have been reviewed.	
SIGNATURE <i>David Hsieh</i>	DATE 01/14/2008
AUTHOR(S) NAME (Print) Hsieh, David, Maj, USAF, MC, FS (Neurology Fellow), and Moorjani, Bhagwan (Neurology Attending)	TELEPHONE (202) 476-2120
OFFICE SYMBOL/ORGANIZATION AFIT	E-MAIL ADDRESS davidhsieh@comcast.net
TECHNICAL REVIEWER CERTIFICATION (Faculty Advisor)	
I certify the information contained in the attached document is technically accurate and does not disclose classified, sensitive, or militarily critical technology and does not violate proprietary rights or copyright restrictions. All security and technology issues listed above have been considered and any applicable security classification guides have been reviewed.	
SIGNATURE <i>Bhagwan Moorjani</i>	DATE 01/14/2008
TECHNICAL REVIEWER'S NAME (Print) Bhagwan Moorjani	TELEPHONE (202) 476-2120
OFFICE SYMBOL/ORGANIZATION Children's National Medical Center	E-MAIL ADDRESS bmoorjani@cnmc.org
DEPARTMENT HEAD (or equivalent)/PROGRAM MANAGER CERTIFICATION	
The attached material submitted for public release has been properly staffed and reviewed by this division/organization. I support the recommendation of the Author and Technical Reviewer for public release.	
SIGNATURE <i>Susan A. Weeks</i>	DATE FEB 08 2008
NAME (Print) SUSAN A. WEEKS, XC-02 Deputy Chief, Medical Education Programs	TELEPHONE 52259 x 3019
OFFICE SYMBOL/ORGANIZATION AFIT/ENEM	
AFIT PUBLIC AFFAIRS	
THE ATTACHED MATERIAL IS/IS NOT CLEARED FOR PUBLIC RELEASE	
SIGNATURE OF SECURITY AND POLICY REVIEW OFFICER <i>Sandy Simon</i>	DATE 13 Feb 08
J. REMARKS (please reference the specific section)	

GENERAL INSTRUCTIONS	
<p>The information provided on this worksheet will be used by the Air Force Institute of Technology Public Affairs Directorate to process requests for Security and Policy Review in accordance with Air Force Instruction 35-101, Chapter 15. Do not use it to request clearance of software source code or web pages.</p> <p>To expedite processing of your request, please print legibly and complete all sections of the worksheet. Space is provided in Section K for additional remarks. If used, please specify the section commented on.</p> <p>Please submit one copy of both this worksheet and the document. We will contact you if additional copies are required. Documents may be submitted in print or digital format (CD-ROM, DVD, or Zip Disk) or VHS videotape.</p>	
SECTION INSTRUCTIONS	
SECTION A:	DOCUMENT TYPE - Identifies the intended presentation format for the information. Place a check in the appropriate box.
SECTION B:	TITLE OF DOCUMENT - Complete document title (<i>Explain abbreviations/acronyms in Section J</i>)
SECTION C:	AUTHOR(S) NAME, DUTY TITLE, OFFICE SYMBOL - Author's first and last name, position or duty title and complete office symbol (e.g., AFIT/PA)
SECTION D:	FORUM - Indicate the method that will be used to present the information. If for presentation at a conference or meeting, provide the full name of the conference or meeting. Provide the location (city, state) and date of the event. If for print media, provide the name of the publication and submission deadline. If related documents have been previously cleared for public release, provide the AFIT case number. (<i>An example of a document that has been previously cleared is as follows: If a thesis has been cleared and you are extracting information from that thesis for another article you have written. Please include the case number of the thesis.</i>)
SECTION E:	NATIONAL SECURITY AND TECHNOLOGY ISSUES - Answer each question and explain positive responses in Section F or J.
SECTION F:	SYNOPSIS - Provide a brief description of the system, process, or technology, including its state of development and whether its application is military, commercial, or dual-use.
SECTION G:	REFERENCES - Check all that apply.
SECTION H:	JOINT AND INTERNATIONAL EFFORTS - Indicate whether or not the information resulted from any effort with an external organization or person or with another DOD or U.S. government agency and specify which organization has release authority and program management responsibility.
SECTION I:	TECHNICAL REVIEW AND CERTIFICATION - The Author and Technical Reviewer (faculty advisor) must certify that the information complies with the statement. (The technical reviewer section applies only when students are submitting documents.) A department head or deputy (or equivalent) or program manager must sign in the second block affirming support for public release.
SECTION J:	REMARKS: Use when additional space is needed to explain a response. Please indicate the section to which the explanation applies. Explain any abbreviations or acronyms.
<p>NOTE:</p> <p>ALL PERSONAL INFORMATION IN THE FOLLOWING CATEGORIES ABOUT U.S. CITIZENS, DOD EMPLOYEES AND MILITARY PERSONNEL SHOULD NOT BE INCLUDED IN THESES, DISSERTATIONS OR OTHER DOCUMENTS THAT WILL BE POSTED ON THE WORLD-WIDE WEB:</p> <ol style="list-style-type: none"> 1) SOCIAL SECURITY ACCOUNT NUMBERS 2) DATES OF BIRTH 3) HOME ADDRESSES 4) TELEPHONE NUMBERS OTHER THAN NUMBERS OF DUTY OFFICERS WHICH ARE APPROPRIATELY MADE AVAILABLE TO THE GENERAL PUBLIC 5) NAMES, LOCATIONS AND ANY OTHER IDENTIFYING INFORMATION ABOUT FAMILY MEMBERS OF DOD EMPLOYEES AND MILITARY PERSONNEL 	

~1. Topic:
Incontinentia pigmenti

~2. Current author name(s)
David T. Hsieh and Bhagwan Moorjani

The views expressed in this article are those of the author and do not reflect the official policy or position of the United States Air Force, Department of Defense, or the U.S. Government.

~2a. Former author name(s)
David A Griesemer (original author), Kimberly N Hutchinson, and Janet C Lam

~2b. Thumbnail
So that MedLink Corporation can highlight your clinical summary and your authorship on the *MedLink Neurology* home page and in our weekly email to subscribers, we ask that you provide here a brief overview of your subject (about 50 to 100 words) aimed at enticing readers to view this clinical summary. *For updates, please include a sentence that refers to something new you have added.* Refer to yourself in the 3rd person (eg, Dr. Doe of Superior Institution explains the basics...). For more information and examples of thumbnails, please see the Instructions to Authors, which can be downloaded from your "My Writing Assignments" page in the Online Submission System (<http://www.medlinkoss.com>).

Current thumbnail:

Incontinentia pigmenti is an X-linked dominant disorder with characteristic skin lesions and anomalies of teeth, hair, nails, eyes, and central nervous system. Cutaneous lesions are the most common identifiable abnormality and characterized in 4 stages. CNS abnormalities are the cause of most morbidity in this disorder. The NEMO gene is identified with this disorder. In this update, Drs. David Hsieh and Bhagwan Moorjani from Children's National Medical Center in Washington, DC highlight the reporting of reversible brain lesions by MRI, and the addition of the gothic palate in the spectrum of oral and dental anomalies in incontinentia pigmenti.

~3. Date of submission: June 1994
Date of update: August 1997
Date of update: April 2001
Date of update: July 18, 2003
Date of update: April 2006
Date of update: January 15, 2007
Date of update: January 15, 2008

~4. Date of MEDLINE search: January 2008





~5. Last reviewed date (*Date displayed in the published Clinical Summary*):
January 22, 2007


~6. Historical note and nomenclature

Incontinentia pigmenti is an X-linked dominant disorder causing ectodermal dysplasia, with characteristic skin lesions and anomalies of teeth, hair, nails, eyes, and central nervous system (McKusick 1990). The disorder was first described by Garrod in 1906 but more clearly defined by Bardach in 1925, Block in 1926, Sulzberger in 1928, and Siemens in 1929 (Landy and Donnai 1993). The multiphasic and multisystemic nature of the disorder was first

recognized by Haber in 1952, at which time the eponym Bloch-Sulzberger syndrome was proposed. In 1961 Lenz first proposed X-linked dominant inheritance (Lenz 1961). The term "incontinentia pigmenti" is a description of the characteristic leakage or "incontinence" of melanin, which appears outside melanocytes in the superficial dermis and basal layer of epidermis.

~7. Clinical manifestations

Cutaneous manifestations, which occur in 96% of familial cases of incontinentia pigmenti, are diagnostic; however, their absence does not exclude the diagnosis. Four overlapping and variable stages have been defined: vesicular, verrucous, hyperpigmented, and atrophic (Berlin 2002). Stage 1 is characterized by erythema and blisters at or shortly after birth. Vesiculo-bullous lesions or pustules appear in a linear pattern along the extremities   or circumferentially around the trunk.  Although several phases of blister formation may occur in different areas, most resolve by age 4 months. Eruptions may recur with febrile illnesses. Stage 2, which can be identified in two thirds of patients (Kegel 1987), is characterized by hyperpigmented, hyperkeratotic papules occurring in the same distribution as earlier blisters. Linear verruciform lesions appear on the hands, feet, and scalp, but they may be subtle and easily overlooked. Although most lesions resolve by age 6 months, they may recur throughout childhood (O'Brien and Feingold 1985). Stage 3 is characterized by the hallmark gray-brown, hyperpigmented macules of incontinentia pigmenti, which occur in 98% of patients (Carney 1976). These occur in streaks or whorls along Blaschko pigmentary lines, predominantly over the trunk in a distribution unrelated to that of earlier vesicles.  Macules become darker over weeks or months, but fade during early adolescence. As many as 40% of incontinentia pigmenti patients are born with verruciform or hyperpigmented lesions of Stage 2 and 3. Stage 4, which can be identified in 14% to 28% of incontinentia pigmenti patients, is characterized by pale streaks, which are most prominent over the calves. These appear lighter in color because of absent hair follicles and reduced vascularity (Moss and Ince 1987).

Systemic manifestations of incontinentia pigmenti are common. However, because it is difficult to recognize mildly-affected incontinentia pigmenti patients, true prevalences may be significantly higher than reported. Dental abnormalities occur in 60% of patients; these may include delayed, absent, or abnormal formation of teeth; teeth are typically peg-shaped or cone-shaped, but have normal enamel (Gorlin and Anderson 1960; Gordon and Gordon 1970; Vogt and Matheson 1991). In addition, the presence of a gothic (high arched) palate has been reported in one series (Minic 2006).  Minor abnormalities of hair and nails are also seen. Almost 50% of patients with incontinentia pigmenti have alopecia and scarring or coarse, wiry hair near the vertex (Carney 1976; Wiklund 1980). Whorled scalp lesions correspond to Blaschko lines of the scalp and may be associated with functional X chromosomal mosaicism (Chan et al 2003). About 40% of patients have nail dystrophy, typically mild but ranging from ridging or pitting to nail disruption or onychogryposis. Painful subungual, hyperkeratotic tumors and underlying deformities of the phalanges are occasionally seen (Hartman 1966; Simmons et al 1986). Supernumerary nipples and nipple or breast hypoplasia are also seen (Landy and Donnai 1993).

Significant neurologic problems occur in 10% to 30% of children with incontinentia pigmenti (Carney 1976; Landy and Donnai 1993), although the spectrum of neurologic abnormalities has not been carefully studied (Shuper et al 1990). Seizure disorders, including infantile spasms, occur in 13% of patients, although satisfactory control is often achieved. Severe mental retardation is seen in 15% of sporadic cases but in only 3% of familial cases (Landy and Donnai 1993). It has been reported that neonatal seizures indicates poor prognosis for normal development (O'Brien 1985), but Bryant and Rutledge (2007) recently reported of a patient with neonatal seizures, and also significant white matter disease by MRI with normal neurologic development. Spasticity occurs in 11% and delayed motor development in 7% (Carney 1976). Neuropathologic findings associated with seizures include polymicrogyria, neuronal heterotopia, and neuronal loss with microcephaly. In addition, ischemic and hemorrhagic cerebral vascular accidents are a recognized complication, though the etiologic pathophysiology is still debated. Other CNS problems include, dysgenesis of the corpus callosum, hydrocephalus, and ataxia (Hauw et al 1977; Tanaka et al 1990; Mangano and Barbagallo 1993; Hennel et al 2003). There has been a report of cortical necrosis and subcortical white matter involvement in a neonate presenting with acute encephalopathy, which was initially misdiagnosed as a viral encephalitis (Wolf et al 2005). Reports have also been made of reversible CNS white matter lesions (Yoshikawa 2000; Lou et al 2007), raising the question of whether CNS involvement occurs more often than previously reported.

Ocular abnormalities have been documented in 33% to 70% of children with incontinentia pigmenti (Rahi and Hungerford 1990; Landy and Donnai 1993; Holmstrom and Thoren 2000). These abnormalities include cataracts, keratitis, strabismus, nystagmus, uveitis, retinal pigment epithelial abnormalities, foveal hypoplasia, vitreous hemorrhage, and optic atrophy (Francois 1984; Lee et al 1995; Ferreira et al 1997). The most common problem is retinal ischemia, which produces extensive vascular remodeling, nonperfusion of retinal capillaries, and neovascular proliferation with subsequent hemorrhage and fibrosis (Heathcote et al 1991). This process is typically self-limited but may progress to clinically significant scarring or retinal detachment (Wald et al 1993). Serious visual impairment has been reported in up to 43% of patients with incontinentia pigmenti (Holmstrom and Thoren 2000).

Other less common anomalies have been reported in the literature as case reports. One report included limb truncation and primary pulmonary hypertension of one patient (Hayes et al 2005). Also reported in the literature is immune dysfunction with lower IgG IgG2 levels in a neonate (Pauly et al 2005).

~7a. Clinical vignette

A 50-day-old girl presented to the ER with 2 days of intermittent facial and body twitching. Her mother described the episodes of twitching as lasting 2 to 3 seconds, occurring primarily with crying and solely involving the right side of her face and right upper and lower extremities. There was no eye deviation, cyanosis, pallor, or apnea associated with the twitching. There was no recent fever or indications of illness. She had good oral intake and good urine output. Birth history was unremarkable. Family history was significant for mother with rash during childhood that gradually resolved by adulthood and maternal history of two prior spontaneous abortions. In the ER, patient was loaded with phenobarbital. Physical exam was significant for a hyperpigmented macular rash with surrounding macular erythema, primarily in the back, arms, and legs in a linear pattern. No vesicles or bullae were noted. Head CT showed nonspecific mild patchy edema of the L cerebral hemisphere. An MRI showed multifocal areas of abnormal restrictive effusions involving the L cerebral hemisphere and corpus callosum consistent with ischemic changes. MRA showed no aneurysms and no stenosis. Ophthalmologic exam was normal. PT/PTT were normal and no further hypercoagulable workup was pursued. EEG showed paucity of higher amplitude slow activity expected during the quiet sleep state. No

seizures were observed during her hospitalization and the patient was discharged with the diagnosis of incontinentia pigmenti.

~8. Etiology

Incontinentia pigmenti is inherited as an X-linked dominant disorder, which is lethal to boys in the prenatal period (Wettke-Schafer and Kanter 1983). This pattern of inheritance explains the dramatically high female to male ratio, female to female transmission, and the increased incidence of spontaneous abortions in families of children with incontinentia pigmenti (Wiklund and Weston 1980; O'Brien and Feingold 1985; Sefiani et al 1991). Approximately half of incontinentia pigmenti children have a family history of the disorder (Carney 1976); the remainder have sporadic mutations. Rarely, incontinentia pigmenti occurs in boys with Klinefelter syndrome (47,XXY) (Ormerod et al 1987; Prendiville et al 1989; Garcia-Dorado et al 1990). A few additional boys are born with incontinentia pigmenti, presumably on the basis of mosaicism, in which cells contain a normal and an abnormal X chromosome (Gorski and Burright 1993). Father to daughter transmission is exceedingly rare (Emery et al 1993).

~9. Pathogenesis and pathophysiology

Originally, 2 distinct gene loci for incontinentia pigmenti were identified on the X chromosome. Sporadic, nonfamilial incontinentia pigmenti has been characterized by autosomal translocations with X-chromosomal breakpoints within region Xp11 (Bernstein et al 1979; Hodgson et al 1985; Kajii et al 1985; Gorski et al 1991; Bitoun et al 1992). More recent data, however, suggest that patients with this translocation do not represent true cases of incontinentia pigmenti (Berlin et al 2002). The more accepted gene for familial incontinentia pigmenti has been mapped to Xq28 (Sefiani et al 1989; Sefiani et al 1991). It has been suggested that in X-linked dominant disorders, cell selection exists against cells expressing the defective allele on their active X chromosome. Non-random (skewed) X inactivation has been documented in only 35% of patients with incontinentia pigmenti (Harris et al 1992); however, it is present in the vast majority of individuals with Xq28-linked incontinentia pigmenti (Parrish et al 1996).

Recently, the gene for NEMO (NF-kappaB essential modulator) and IKK gamma (IkappaB kinase-gamma) has been mapped to 200 kilobases proximal to the factor VIII gene in Xq28. This gene is responsible for activating the transcription factor NF-kappaB, which is an important mediator in immune, inflammatory, and apoptotic pathways. Most incontinentia pigmenti patients have mutations of the NEMO gene. Ninety percent of cases were attributed to an identical genomic deletion (exons 4 to 10), resulting in genomic rearrangements at the NEMO locus (The International Incontinentia Pigmenti Consortium 2000; Smahi et al 2000; Aradhya et al 2001). Mutations of NEMO, which do not abolish NF-kappaB activity totally, permit male survival, causing an allelic variant of incontinentia pigmenti called hypohidrotic ectodermal dysplasia and immunodeficiency (HED-ID) (Martinez-Pomar et al 2005). It has been suggested that the apoptosis function associated with NF-kappaB accounts for much of the incontinentia pigmenti phenotype, including the retinal and central nervous system manifestations. Failure of the cells to resist apoptosis results in early cell death. Limb truncation likely related to the defect in NF-kappa B gene, which is responsible for formation of the apical ectodermal ridge at the tip of limb buds (Hayes et al 2005). Cytokines, growth factor, and modulators also interact with NF-kappa B and may explain the primary pulmonary hypertension documented in the literature (Hayes et al 2005). The modulation of immune function by NF-kappaB is likely related to the immune dysfunction reported in the literature (Pauly 2005).

Special interest has also been paid to eotaxin, an eosinophil-selective chemokine that has been isolated from the blister fluid of incontinentia pigmenti lesions. The promoter for eotaxin has an NF-kappaB binding site, and immunohistochemical staining of skin lesions from incontinentia pigmenti patients demonstrated strong expression of eotaxin throughout most of

the epidermal layers (Berlin et al 2002). Additionally, the X-inactivation status in female individuals contributes to the wide variety of phenotypes associated with this single common deletion (Aradhya et al 2001). Others have postulated that clinical findings result from an autoimmune attack on ectodermal cells, which express a surface antigen controlled by the mutant X chromosome gene (Person 1985).

MR imaging suggests the possibility of prenatal ischemic injury as a mechanism for occasional incontinentia pigmenti-related structural changes in the CNS (Mangano and Barbagallo 1993). Progressive microvascular changes may be a common pathogenesis of retinal and some CNS abnormalities (Lee et al 1995). MRI may demonstrate multiple scattered foci of restricted diffusion and decreased T2 signal within the periventricular white matter consistent with microvascular hemorrhagic infarcts. These abnormalities may progress to hemorrhagic necrosis. MRA may reveal decreased branching and poor filling of the distal middle and posterior cerebral arteries (Hennel et al 2003). These abnormalities have been postulated to relate to cerebral or cerebrovascular anomalies similar to those in the retina (Fiorillo et al 2003). Vascular abnormalities and occlusion of the retinal vessels are well described in the literature. It is possible that the retinal and cerebral vasculature share the same vulnerability due to inflammation or a hypersensitivity reaction to an abnormal protein expressed from a mutant gene (Lee et al 1995). Additionally, a microangiopathic process in the lungs may result in primary pulmonary hypertension (Hayes et al 2005).

~10. Epidemiology

Approximately 1 in 50,000 newborns are affected (Aradhya et al 2001). Skin involvement is the most common sign and 86% have stage I or II lesions, 80% were found to have stage III lesions, and 92% had stage IV lesions. Neurologic involvement, notably moderate to severe intellectual deficit was 8%. 37% were found to have eye abnormalities, the most common being strabismus. 95% had dental abnormalities. The NEMO gene deletion has been found in 80% to 90% of newborns (Phan et al 2005).

~11. Prevention

No information was provided by the author.

~12. Differential diagnosis

Early cutaneous findings must be distinguished from vesicular or bullous lesions common at birth. Noninfectious causes include erythema toxicum neonatorum, epidermolysis bullosa, dermatitis herpetiformis, drug eruptions, erythema multiforme, and neonatal lupus (Nelson-Adesokan and Mallory 1992), whereas common infectious causes include bullous impetigo, herpes simplex, and varicella zoster. Disorders that exhibit linear cutaneous lesions must also be distinguished from incontinentia pigmenti. One of these is hypomelanosis of Ito, which is also called incontinentia pigmenti *achromians*. Clinical findings in hypomelanosis of Ito include mental retardation, seizures, skeletal dysplasia, and depigmentation following Blaschko lines, resulting from a decrease in melanin in the basal layer of epidermis. Another disorder is X-linked chondrodysplasia punctata, which is distinct because of its linear scarring with follicular pitting, skeletal dysplasia, and congenital cataracts. Finally, disorders of hyperpigmentation must be differentiated from incontinentia pigmenti. Examples include multisystem disorders with café-au-lait or brown spots, such as neurofibromatosis, Silver-Russell syndrome, tuberous sclerosis, and Albright syndrome (Fulk 1984; Zillikens et al 1991). The differential diagnosis of vesicular and linear lesions is broad, and a dermatologist should be consulted if diagnostic questions remain. However, the presence of primary skeletal abnormalities or severe neurologic impairment in early stages makes the diagnosis of incontinentia pigmenti less likely.

~13. Diagnostic workup

No information was provided by the author.

~14. Prognosis and complications

Patients with incontinentia pigmenti appear to be at increased risk of CNS infection (Siemes et al 1978; Diamantopoulos et al 1985; Barson and Reiner 1986), which may be related to defective neutrophil chemotaxis (Menni et al 1990). Although infrequent, other reported CNS complications include hemorrhagic or necrotic encephalopathy (McPherson and Auth 1963; Siemes et al 1978; Avrahami et al 1985; Shuper et al 1990), recurrent encephalomyelitis and optic neuritis with depletion of T8 suppressor cells and increase in the T4:T8 ratio (Brunquell 1987), and anterior horn cell degeneration (Larsen et al 1987). Risk of malignancy also appears to be increased in incontinentia pigmenti children under age 3 years (Roberts et al 1988). Late reactivation is possible, but rare, and most often associated with viral or bacterial infection (Patrizi et al 2004). At an older age, the following may occur: slowing down of motor function, muscular weakness, mental retardation, and convulsions (Buinauskiene et al 2005).

~15. Management

Clinical diagnosis on the basis of the hallmark hyperpigmented lesions in whorling or linear patterns is often possible. However, during the vesicular or verruciform stages, skin biopsy and direct immunofluorescence is helpful. In Stage 1, histologic studies show intraepidermal infiltration of eosinophils. In Stage 2, the epidermis is acanthotic and hyperkeratotic with papillomatosis (Lever and Schaumburg-Lever 1990). In Stage 3, melanin is seen in the papillary dermis, and vacuoles are seen in the basal cell layer. Electron microscopy shows gaps in the basement membrane where fetal nerves enter the epidermis (Worrett et al 1988). In Stage 4, there is epidermal atrophy with reduced melanocytes and absence of adnexal structures (Lever and Schaumburg-Lever 1990; Nazzaro et al 1990; Zillikens et al 1991). Colloid bodies similar to Civatte bodies of lichen planus and lupus erythematosus have also been identified in the upper dermis by means of electron microscopy (Berlin et al 2002). Histologic examination is especially important with atypical symptoms that may suggest chromosomal mosaicism. Biopsy may also be helpful with older children or adults in whom cutaneous findings may be minimal. Bedside diagnosis in neonates may be facilitated by unroofing a vesicle and observing eosinophils in the fluid under light microscopy. A Tzanck preparation, bacterial and viral cultures, and complete blood count may further narrow the differential diagnosis (Nelson-Adesokan and Mallory 1992), as significant leukocytosis with eosinophilia is seen during the vesicular stage of incontinentia pigmenti (Carney 1976). The presence of cone-shaped teeth, nail dysplasia, patchy alopecia, or retinal dysplasia may further suggest the need for biopsy in children who do not have typical cutaneous involvement.

Increased use of MR angiography and spectroscopy has permitted the identification of acute or chronic cerebrovascular disease not previously recognized. MR findings reported in patients with incontinentia pigmenti include small vessel occlusions, hypoplasia of the corpus callosum, enlargement of the lateral ventricles, and periventricular white matter disease (Lee et al 1995; Aydingoz and Midia 1998). Because neuroimaging have not been routinely ordered in incontinentia pigmenti, the frequency of CVA may be underestimated (Fiorillo et al 2003).

Periodic neurologic and psychoeducational evaluations of patients with incontinentia pigmenti should be performed to identify motor, developmental, or cognitive problems. MR imaging is recommended to document dysplastic or ischemic brain malformations. Standard strategies for treatment of infantile spasms or other seizures are required in some patients; however, subclinical epileptiform discharges may be seen in others (Bitoun et al 1992). Because of ocular anomalies associated with incontinentia pigmenti, serial retinal examination is recommended during the first year of life. Fluorescein angiography may be recommended to further evaluate occult areas of neovascularization and leakage that may progress to retinal

detachment and decreased vision (Shaikh et al 2004). Retinal neovascularization may be treated with xenon photocoagulation (Nishimura et al 1980) or cryotherapy (Rahi and Hungerford 1990). Retinal detachment may require vitreous surgery (Wald et al 1993). The prognosis for normal vision is excellent if incontinentia pigmenti children do not have retinal abnormalities during the first year of life (Rahi and Hungerford 1990). Finally, regular dental evaluations are important to plan for orthodontic treatment in selected patients.

Comprehensive genetic counseling is essential. It is important to obtain a family history, including history of spontaneous abortions, and to examine all women and girls in the family as potential gene carriers. Because girls with sporadic incontinentia pigmenti are often severely affected, chromosome analysis is indicated for patients with atypical or severe symptoms and all presumably affected boys (Gorski and Burright 1993). Genetic testing for the common NEMO gene mutation is now available. This testing is performed at Baylor College of Medicine DNA Diagnostic Laboratory (Houston, Texas; phone: 800-BCM-DNA4; Web site: <http://www.bcmgeneticlabs.org>)).

Support groups and additional educational information for patients and their families is available through the [Incontinentia Pigmenti International Foundation](http://imgen.bcm.tmc.edu/ipif/) (30 East 72nd St, 16th Floor, New York, NY 10021; phone: 212-452-1231) and the Incontinentia Pigmenti Support Network (34929 Elm, Wayne, MI 48184; phone: 313-729-7912) (Berlin et al 2002).

~16. Pregnancy

A woman with incontinentia pigmenti has a 50% chance of contributing a normal X chromosome and a 50% chance of contributing an abnormal X chromosome to each child. The daughter or son receiving a normal X chromosome will be unaffected. The daughter receiving an abnormal X chromosome from the mother and a normal X chromosome from the father will have incontinentia pigmenti. The son receiving an abnormal X chromosome from the mother and a normal Y chromosome from the father, will also have incontinentia pigmenti but will likely die in utero. The frequency of spontaneous abortions in familial incontinentia pigmenti is 23%, corresponding to the 1 in 4 chance of a child receiving the incontinentia pigmenti-mutated X chromosome from the mother and a Y chromosome from the father (Wettke-Schafer and Kanter 1983).

~17. Anesthesia

No information was provided by the author.

~18. References cited

Aradhya S, Woffendin H, Jakins T, et al. A recurrent deletion in the ubiquitously expressed NEMO (IKK-gamma) gene accounts for the vast majority of incontinentia pigmenti mutations. *Hum Mol Genet* 2001;10(19):2171-9.

Avrahami E, Harel S, Jurgenson U, Cohn DF. Computed tomographic demonstration of brain changes in incontinentia pigmenti. *Am J Dis Child* 1985;139:372-4.

Aydingoz U, Midia M. Central nervous system involvement in incontinentia pigmenti: cranial MRI of two siblings. *Neuroradiology* 1998;40:364-6.

Barson WJ, Reiner CB. Coxsackievirus B2 infection in a neonate with incontinentia pigmenti. *Pediatr* 1986;77:897-900.

Berlin A, Paller A, Chen L. Incontinentia pigmenti: a review and update on the molecular basis of pathophysiology. *J Am Acad Dermatol* 2002;47(2):169-87.

Bernstein R, Dawson B, Kohl R, Jenkins T. X;15 translocation in a retarded girl. X inactivation pattern and attempt to localize the hexosaminidase A and other loci. *J Med Genet* 1979; 16:254-62.

Bitoun P, Philippe C, Cherif M, Mulchahy MT, Gilgenkrantz S. Incontinentia pigmenti (type 1) and X;5 translocation. *Ann Genet* 1992;35:51-4.

Brunquell PJ. Recurrent encephalomyelitis associated with incontinentia pigmenti. *Pediatr Neurol* 1987;3:174-7.

Bryant SA and Rutledge SL. Abnormal white matter in a neurologically intact child with incontinentia pigmenti. *Pediatr Neurol* 2007; 36: 199-201.

Buinauskiene J, Buinauskiene E, Valiukeviciene S. Incontinentia pigmenti (Bloch-Sulzberger syndrome) in neonates. *Medicina* 2005;41(6):496-9.

Carney RG. Incontinentia pigmenti: a world statistical analysis. *Arch Dermatol* 1976;112:535-42.

Chan Y, Happle R, Giam Y. Whorled scarring alopecia: A rare phenomenon in incontinentia pigmenti? *J Am Acad Dermatol* 2003;49(5):929-31.

Diamantopoulos N, Bergman I, Kaplan S. Actinomyces in a girl with incontinentia pigmenti. *Clin Pediatr* 1985;24:651-4.

Emery MM, Siegfried EC, Stone MS, Stone EM, Patil SR. Incontinentia pigmenti. Transmission from father to daughter. *J Am Acad Dermatol* 1993;29:368-72.

Ferreira RC, Ferreira LC, Forstot L, King R. Corneal abnormalities associated with incontinentia pigmenti. *Am J Ophthalmol* 1997;123:549-51.

Fiorillo L, Sinclair DB, O'Byrne, ML, Krol AL. Bilateral cerebrovascular accidents in incontinentia pigmenti. *Pediatr Neurol* 2003;29(1):66-8.

Francois J. Incontinentia pigmenti (Bloch-Sulzberger syndrome) and retinal changes. *Br J Ophthalmol* 1984;68:19-25.

Fulk CS. Primary disorders of hyperpigmentation. *J Am Acad Dermatol* 1984;10:1-16.

Garcia-Dorado J, de Unamuno P, Fernandez-Lopez E, Salazar Veloz J, Armijo M. Incontinentia pigmenti: XXY male with family history. *Clin Genet* 1990;38:128-38.

Gordon H, Gordon W. Incontinentia pigmenti: clinical and genetical studies of two familial cases. *Dermatologica* 1970;140:150-68.

Gorlin RJ, Anderson JA. The characteristic dentition of incontinentia pigmenti. *J Pediatr* 1960;57:78-85.

Gorski JL, Burright EN. The molecular genetics of incontinentia pigmenti. *Semin Dermatol* 1993;12:255-65.

Gorski JL, Burright EN, Harnden CE, Stein CK, Glover TW, Reyner EL. Localization of DNA sequences to a region within Xp11.21 between incontinentia pigmenti (IP1) X-chromosomal translocation break points. *Am J Hum Genet* 1991;48:53-64.

Harris A, Collins J, Vetrie D, Cole C, Bobrow M. X inactivation as a mechanism of selection against lethal alleles. Further investigation of incontinentia pigmenti and X linked lymphoproliferative disease. *J Med Genet* 1992;29:608-14.

Hartman DL. Incontinentia pigmenti associated with subungual tumors. *Arch Dermatol* 1966;94:632-5.

Hauw JJ, Perie G, Bonnette J, Escourolle R. Les lésions cérébrales de l'incontinentia pigmenti. A propos d'un cas anatomique. *Acta Neuropathol* 1977;38:159-62.

Hayes I, Varigos G, Upjohn E, Orchard D, Penny D, Savariraya. Unilateral acheiria and fatal primary pulmonary hypertension. *Am J Med Genet A* 2005;135(3):302-3.

Heathcote JG, Schoales BA, Willis NR. Incontinentia pigmenti (Bloch-Sulzberger syndrome). A case report and review of the ocular pathological features. *Can J Ophthalmol* 1991;26:229-37.

Hennel AJ, Ekert PG, Volpe JJ, Inder TE. Insights into the pathogenesis of cerebral lesions in incontinentia pigmenti. *Pediatric Neurology* 2003;29(2):148-50.

Hodgson SV, Neville B, Jones RWA, Fear C, Bobrow M. Two cases of X-autosome translocation in females with incontinentia pigmenti. *Hum Genet* 1985;71:231-4.

Holmstrom G, Thoren K. Ocular manifestations of incontinentia pigmenti. *Acta Ophthalmol Scand* 2000;78:348-53.

Kajii T, Tsukahara M, Fukushina Y, Hata A, Matsuo K, Kuroki Y. Translocation (X;13)(p11.21;q12.3) in a girl with incontinentia pigmenti and bilateral retinoblastoma. *Ann Genet* 1985;28:219-23.

Kegel MF. Dominant disorders with multiple organ involvement. *Dermatol Clin* 1987;5:205-19.

Landy SJ, Donnai D. Incontinentia pigmenti (Bloch-Sulzberger syndrome). *J Med Genet* 1993;30:53-9.

Larsen R, Ashwal S, Peckham N. Incontinentia pigmenti. Association with anterior horn cell degeneration. *Neurology* 1987;37:446-50.

Lee AG, Goldberg MF, Gillard JH, Barker PB, Bryan RN. Intracranial assessment of incontinentia pigmenti using magnetic resonance imaging, angiography, and spectroscopic imaging. *Arch Pediatr Adolesc Med* 1995;149:573-80.

Lenz W. Zur Genetik der Incontinentia Pigmenti. *Ann Paediatr (Basel)* 1961;196:149-65.

Lever WF, Schaumburg-Lever G. Congenital diseases (genodermatoses). In: *Histopathology of the skin*. Philadelphia: JB Lippincott, 1990:93-5.

Lou H, Zhang L, Xiao W, et al. Nearly complete reversible brain abnormalities in a patient with incontinentia pigmenti. *Am J Neurorad* 2008; 1-3.

Mangano S, Barbagallo A. Incontinentia pigmenti. Clinical and neuroradiologic features. *Brain Dev* 1993;15:362-6.

Martinez-Pomar N, Munoz-Saa I, Heine-Suner D, et al. A new mutation in exon 7 of NEMO gene: late skewed X chromosome inactivation in an incontinentia pigmenti female patient with immunodeficiency. *Hum Genet* 2005;118:458-65.

McKusick VA. Mendelian inheritance in man. Catalogs of autosomal dominant, autosomal recessive, and X-linked phenotypes. 9th ed. Baltimore: Johns Hopkins Univ Pr, 1990.

McPherson A, Auth TL. Bloch-Sulzberger syndrome (incontinentia pigmenti). Report of a case with prominent neurological features. *Arch Neurol* 1963;8:116-23.

Menni S, Piccinno R, Biolchini A, Plebani A. Immunologic investigations in eight patients with incontinentia pigmenti. *Pediatr Dermatol* 1990;7:275-7.

Minic S, Novotny GE, Trpinac D, and Obradovic M. Clinical features of incontinentia pigmenti with emphasis on oral and dental abnormalities. *Clin Oral Investig* 2006; 10: 343-7.

Moss C, Ince P. Anhydrotic and chromans lesions in incontinentia pigmenti. *Br J Dermatol* 1987;116:839-50.

Nazzaro V, Brusasco A, Gelmetti C, Ermacora E, Caputo R. Hypochromic reticulated streaks in incontinentia pigmenti: an immunohistochemical and ultrastructural study. *Pediatr Dermatol* 1990;7:174-8.

Nelson-Adesokan P, Mallory SB. Incontinentia pigmenti. *Pediatr Dermatol* 1992;9:304-8.

Nishimura M, Oka Y, Takagi I. The clinical features and treatment of the retinopathy of Bloch-Sulzberger syndrome (incontinentia pigmenti). *Jpn J Ophthalmol* 1980;24:310-9.

O'Brien JE, Feingold M. Incontinentia pigmenti. A longitudinal study. *Am J Dis Child* 1985;139:711-2.

Ormerod AD, White MI, McKay E, Johnston AW. Incontinentia pigmenti in a boy with Klinefelter's syndrome. *J Med Genet* 1987;24:439-41.

Parrish JE, Scheuerle AE, Lewis RA, Levy ML, Nelson DL. Selection against mutant alleles in blood leukocytes is a consistent feature in incontinentia pigmenti type 2. *Hum Mol Genet* 1996;5:1777-83.

Pauly E, Linderkamp O, Poschl J. Incontinentia pigmenti in combination with decreased IgG subclass concentrations in a female newborn. *Biol Neonate* 2005;88(3):172-4.

Patrizi A, Neri I, Guareschi E, Cocchi G. Bullous recurrent eruption of incontinentia pigmenti. *Pediatr Dermatol* 2004;21(5):613-4.

Person JR. Incontinentia pigmenti. A failure of immune tolerance? J Am Acad Dermatol 1985;13:120-2.

Phan T, Wargon O, Turner A. Incontinentia pigmenti case series: clinical spectrum of incontinentia pigmenti in 53 female patients and their relatives. Clin Exp Dermatol 2005;30(5):474-80.

Prendiville JS, Gorski JL, Stein CK, Esterly NB. Incontinentia pigmenti in a male infant with Klinefelter syndrome. J Am Acad Dermatol 1989;20:937-40.

Rahi J, Hungerford JR. Early diagnosis of the retinopathy of incontinentia pigmenti. Successful treatment by cryotherapy. Br J Ophthalmol 1990;74:377.

Roberts WM, Jenkins JJ, Moorhead EL, Douglass EC. Incontinentia pigmenti, a chromosomal instability syndrome, is associated with childhood malignancy. Cancer 1988;62:2370-3.

Sefiani A, Abel L, Heuertz S, et al. The gene for incontinentia pigmenti is assigned to Xq28. Genomics 1989;4:427-9.

Shaikh S, Trese M, Archer S. Florescein angiographic findings in incontinentia pigmenti. 2004;24(4):628-9.

Shuper A, Bryan RN, Singer HS. Destructive encephalopathy in incontinentia pigmenti. A primary disorder? Pediatr Neurol 1990;6:137-40.

Sefiani A, M'rad R, Simard L, et al. Linkage relationship between incontinentia pigmenti (IP2) and nine terminal X long arm markers. Hum Genet 1991;86:297-9.

Siemes H, Schneider H, Hanefeld F. Encephalitis in two members of a family with incontinentia pigmenti (Bloch-Sulzberger syndrome). Eur J Pediatr 1978;129:103-15.

Simmons DA, Kegel MF, Scher RK, Hines YC. Subungual tumors in incontinentia pigmenti. Arch Dermatol 1986;122:1431-4.

Smahi A, Courtois G, Vabres P et al. Genomic rearrangement in NEMO impairs NF-kappaB activation and is a cause of incontinentia pigmenti. Nature 2000;405:466-72.

Tanaka K, Kambe N, Fujita M, Ando Y, Takashima S, Yuasa I. Incontinentia pigmenti in identical twins with separate skin and neurological disorders. Acta Derm Venereol (Stockh) 1990;70:267-8.

The International Incontinentia Pigmenti Consortium. "Genomic rearrangement in NEMO impairs NF-kB activation and is a cause of incontinentia pigmenti." Nature 2000;405:466-72.

Vogt J, Matheson J. Incontinentia pigmenti (Bloch-Sulzberger syndrome). A case report. Oral Surg Oral Med Oral Pathol 1991;71:454-6.

Wald KJ, Mehta MC, Katsumi O, Sabates NR, Hirose T. Retinal detachments in incontinentia pigmenti. Arch Ophthalmol 1993;111:614-7.

Wettke-Schafer R, Kanter G. X-linked dominant inherited diseases with lethality in hemizygous males. *Hum Genet* 1983;64:1-23.

Wiklund DA, Weston WL. Incontinentia pigmenti. A four generational study. *Arch Dermatol* 1980;116:701-3.

Wolf N, Kramer N, Harting I, Seltz A, Ebinger F, Poschl J. Diffuse cortical necrosis in a neonate with incontinentia pigmenti. *Am J Neuroradiol* 2005; 26(6):1580-2.

Worrett WI, Nordquist RE, Burgdorf WHC. Abnormal cutaneous nerves in incontinentia pigmenti. *Ultrastruct Pathol* 1988;12:449-54.

Yoshikawa H, Uehara Y, Abe T, and Oda Y. Disappearance of a white matter lesion in incontinentia pigmenti. *Pediatr Neurol* 2000; 23: 364-367.

Zillikens D, Mehninger A, Lechner W, Burg G. Hypo- and hyperpigmented areas in incontinentia pigmenti light and electron microscopic studies. *Am J Dermatopathol* 1991;13:57-62.

****References especially recommended by the author or editor for general reading.**

~19. Abbreviations

CNS:central nervous system
CT:computed tomography
MR:magnetic resonance

~20. ICD codes

ICD-9:

Incontinentia pigmenti: 757.33

ICD-10:

Incontinentia pigmenti: Q82.3

~20a. OMIM number

Incontinentia pigmenti: #308300

~21. Synonyms

Bloch-Sulzberger syndrome

~24. Major keyword descriptors

Blaschko lines
ectodermal dysplasia
hyperpigmentation
infantile spasms
neurocutaneous syndrome
phakomatosis
rash
retinal detachment
retinal neovascularization
seizures
spasticity
vesicles

X-chromosome
CVA

~25. Minor keyword descriptors

anterior horn cell
cerebral dysgenesis
dental abnormality
eosinophilia
Klinefelter syndrome
microcephaly
microphthalmos
mosaicism
nystagmus
optic nerve atrophy
strabismus

~26. Age of presentation

0-01 month
01-23 months
02-05 years
06-12 years
13-18 years
19-44 years
45-64 years
65+ years

~27. Age of typical presentation

0-01 month
01-23 months
02-05 years

~28. Population group(s) preferentially affected
none selectively affected

~30. Occupation group(s) preferentially affected
none selectively affected

~32. Sex

female>male, >2:1
female>male, >1:1

~33. Family history
family history typical

~34. Heredity

heredity typical
heredity may be a factor
X-linked dominant

~36. Permuted topic, synonyms, subtopics
Incontinentia pigmenti

pigmenti, Incontinentia
Sulzberger syndrome, Bloch-

~37. Related topics

Focal cortical dysplasia

Hypomelanosis of Ito

Neurocutaneous syndromes

~38. Differential diagnosis

vesicular lesions

bullous lesions

hypomelanosis of Ito

incontinentia pigmenti *achromians*

X-linked chondrodysplasia punctata

hyperpigmentation

neurofibromatosis

Silver-Russell syndrome

tuberous sclerosis

Albright syndrome

erythema toxicum neonatorum

epidermolysis bullosa

dermatitis herpetiformis

drug eruptions

erythema multiforme

neonatal lupus

bullous impetigo

herpes simplex

varicella zoster

~